XML 67 R60.htm IDEA: XBRL DOCUMENT v3.25.1
Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share (Details) - shares
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Antidilutive securities 26,903,438 25,974,828
Employee Stock Option    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Antidilutive securities 11,968,545 13,085,872
Nonvested Restricted Stock Units Outstanding    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Antidilutive securities 10,598,610 10,341,199
Nonvested Performance-based Restricted Stock Units Outstanding    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Antidilutive securities 24,995  
Nonvested Market-based Restricted Stock Units Outstanding Granted    
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]    
Antidilutive securities 4,311,288 2,547,757